


5

CLAIMS


What is claimed is:

1. A compound comprising




10

or a pharmaceutically acceptable salt or a prodrug thereof,
 wherein a dashed line indicates the presence or absence of a bond, and an (H)
 represents a hydrogen atom which is present if required by said bond;
 Y is selected from the group consisting of CO₂H, CONMe₂, CONHMe,
 15 CONHEt, CON(OCH₃)CH₃, CONH₂, CON(CH₂CH₂OH)₂,
 CONH(CH₂CH₂OH), CH₂OH, P(O)(OH)₂, CONHSO₂CH₃, SO₂NH₂,
 SO₂N(CH₃)₂, SO₂NH(CH₃),




R is selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, halogen,
 20 CO₂H, OH, COH, COCH₃, COCF₃, NO₂, CN, and CF₃.

2. The compound of claim 1 comprising




or a pharmaceutically acceptable salt or a prodrug thereof.

- 5 3. The compound of claim 2 comprising




or a pharmaceutically acceptable salt or a prodrug thereof.

4. The compound of claim 3 consisting of




- 10 5. The compound of claim 1 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.

- 5 6. A compound having an ω chain comprising




or a derivative thereof,

wherein a dashed line indicates the presence or absence of a bond, and an (H) represents a hydrogen atom which is present if required by said bond;

- 10 wherein said derivative has a structure as shown above except that an alteration is made to said structure, wherein an alteration consists of

- a. adding, removing, or substituting a non-hydrogen atom of the ω chain;
- b. converting a CO_2H to a moiety selected from the group consisting of



- c. converting a phenyl moiety to a pyridinyl, furyl, thienyl, or *n*-butyl moiety; or
- d. adding a substituent comprising from 1 to 3 non-hydrogen atoms to a phenyl moiety;

or a pharmaceutically acceptable salt or a prodrug thereof.

7. The compound of claim 1 comprising
- 25 4-{2-[(R)-2-((E)-3-Hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-ethylsulfanyl}-butyric acid methyl ester, or

5 4-{2-[(R)-2-((E)-3-Hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-
ethylsulfanyl}-butyric acid,


or a pharmaceutically acceptable salt or a prodrug thereof.

8. The compound of claim 1 consisting of

4-{2-[(R)-2-((E)-3-Hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-
10 ethylsulfanyl}-butyric acid methyl ester, or

4-{2-[(R)-2-((E)-3-Hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-
ethylsulfanyl}-butyric acid.


9. A method comprising administering an effective amount of a compound
to a mammal, said method being effective in treating or preventing glaucoma or
15 intraocular hypertension, wherein said compound comprises



or a pharmaceutically acceptable salt or a prodrug thereof,


wherein a dashed line indicates the presence or absence of a bond, and an (H)
represents a hydrogen atom which is present if required by said bond;

20 Y is selected from the group consisting of CO₂H, CONMe₂, CONHMe,
CONHEt, CON(OCH₃)CH₃, CONH₂, CON(CH₂CH₂OH)₂,
CONH(CH₂CH₂OH), CH₂OH, P(O)(OH)₂, CONHSO₂CH₃, SO₂NH₂,
SO₂N(CH₃)₂, SO₂NH(CH₃),



25 R is selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, halogen,
CO₂H, OH, COH, COCH₃, COCF₃, NO₂, CN, and CF₃.

10. A liquid composition comprising an effective amount of a compound
having an ω chain comprising



5

or a derivative thereof,

wherein a dashed line indicates the presence or absence of a bond, and an (H)


represents a hydrogen atom which is present if required by said bond;

wherein said derivative has a structure as shown above except that an alteration is

made to said structure, wherein an alteration consists of

- a. adding, removing, or substituting a non-hydrogen atom of the ω chain;
- b. converting a CO_2H to a moiety selected from the group consisting of CONMe_2 , CONHMe , CONHEt , $\text{CON}(\text{OCH}_3)\text{CH}_3$, CONH_2 , $\text{CON}(\text{CH}_2\text{CH}_2\text{OH})_2$, $\text{CONH}(\text{CH}_2\text{CH}_2\text{OH})$, CH_2OH , $\text{P}(\text{O})(\text{OH})_2$, $\text{CONHSO}_2\text{CH}_3$, SO_2NH_2 , $\text{SO}_2\text{N}(\text{CH}_3)_2$, $\text{SO}_2\text{NH}(\text{CH}_3)$,

15



, and

- c. converting a phenyl moiety to a pyridinyl, furyl, thienyl, or *n*-butyl moiety; or

- d. adding a substituent comprising from 1 to 3 non-hydrogen atoms to a phenyl moiety;

20

or a pharmaceutically acceptable salt or a prodrug thereof; and

wherein said composition is intended for topical ophthalmic use.

25